• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    New survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women

    5/7/25 10:02:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email

    Star Jones, award winning television personality & women's heart health advocate, helps kick off heart health conversations this Mother's Day with the Medtronic 'Letter to My Mother' campaign

    GALWAY, Ireland, May 7, 2025 /PRNewswire/ -- A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their mother-figures. Despite cardiovascular disease being the #1 killer of women in the U.S., many women are still unaware of the risk and the importance of heart health.

    The survey, endorsed by WomenHeart and conducted by Wakefield Research, found that nearly half of women (45%) were more likely to discuss sensitive topics such as politics, money, or relationships with their mother or grandmother before discussing family heart health history, despite the fact that as much as half of the risk for heart disease is hereditary.

    For more than a century, heart disease has remained the leading cause of death in women, accounting for more deaths than all cancers combined. Yet, when it comes to serious heart concerns, women are up to 35% less likely to be treated with proven, minimally invasive solutions for heart valve failure than men, and women account for more than half (52%) of deaths caused by high blood pressure.1 Additionally, women often experience heart attack symptoms differently, and heart disease disproportionately impacts women of color, with 43% of Hispanic women and 59% of Black women experiencing some form of cardiovascular disease.

    The Medtronic Letter to My Mother campaign encourages women to make heart health a priority, starting with a conversation with their mother, or a woman in their life, about family history, risk factors, and the signs and symptoms of heart disease. The campaign, part of the company's ongoing commitment to leading and advancing clinical research for women's health, seeks to close the gap in awareness of heart disease and risks—particularly heart valve failure and high blood pressure—in women.

    "The U.S. is at a tipping point when it comes to women's health, and heart health remains the deadliest concern of all," said Nina Goodheart, senior vice president and president, Structural Heart & Aortic, which is part of the Cardiovascular Portfolio at Medtronic. "At Medtronic, we're working relentlessly to ensure women receive personalized, evidence-based healthcare solutions, tailored to them. The launch of Letter to My Mother marks another step in our sustained commitment to improving health outcomes for all."

    Results from the survey reveal a surprising disconnect between what women fear for their mothers or mother-figures as they age and the actual conversations happening around family health history:

    • More than half of women (53%) worry that as their mothers age, they will ignore symptoms or fail to inform them when something is wrong.
    • Yet, over half (56%) admit they have never discussed heart health with their mothers or other women in their family.
    • For those with a family history of heart disease, only one-third (35%) asked their doctor to assess their heart risk.  
    • Only 44% of these same women actually talked about it with their mothers or mother-figures.

    "As women, we are our own best advocates, but without the confidence, knowledge, or resources to discuss our health history, we are missing out on potential life-saving conversations," said Star Jones, attorney, award-winning television personality & longtime women's heart health advocate. "I come from a family with a long history of heart disease, yet this was rarely a topic we talked about. If only I had acknowledged my risk for heart disease earlier, I could've potentially addressed my concerns with my cardiologist sooner before it led to needing open-heart surgery. That is why I am speaking out now to get all women talking about this disease and how addressing symptoms could save their life – like it did for me."

    The survey also revealed that personal heart health is often overlooked by women in the sandwich generation, the population of women who bear the weight of making healthcare decisions for their children, parents, and family members. Almost all (94%) of women surveyed are responsible for making health-related decisions for loved ones, but over 60% of women find it hard to make their own health a priority. 

    "As physicians, we know heart health is not one size fits all. Women have a unique experience with heart disease and risk factors - like high blood pressure during pregnancy which may be the first sign of chronic high blood pressure persisting throughout their lifespan," said Dr. Raven Voora, hypertension specialist and nephrologist at UNC Health. "Too often, I've seen women present with risk factors or early signs of heart disease that they put on the backburner behind care for children and loved ones - or these signs and symptoms get brushed off as stress or anxiety. This survey shows us that patients need increased awareness and discussion surrounding heart health and to make sure they pay attention to their heart health."

    This May, during Women's Health Month and timed to Mother's Day – Medtronic encourages people to take the pledge to talk to their mother or the women in their life about heart health today. For every pledge, Medtronic will make a donation to a cause that advances women's heart health.

    Visit Alettertomymother.com to take the pledge and learn more.

    About the Medtronic Letter to My Mother Survey:

    Medtronic engaged Wakefield Research to conduct a nationally representative survey to gain insights into consumer perceptions and awareness of heart disease in women aged 30 through 50, targeted to the "daughters" who are sandwiched between taking care of their health, their children and parents. The survey was deployed among 1,000 U.S. women, ages 30 to 50, with a living mother and a living child, between March 13th and March 17th, 2025, using an email invitation and an online survey.

    Survey results are endorsed by WomenHeart: The National Coalition for Women with Heart Disease, the nation's leading voice for women living with or at risk of heart disease. WomenHeart is dedicated to promoting awareness, advocacy, and support for women with heart disease, empowering them to take charge of their heart health and improve outcomes.

    About the Medtronic Letter to My Mother Campaign:

    The Medtronic "Letter to My Mother" campaign aims to educate and close the gap in awareness of heart disease in women — the number one cause of death for more than a century. The campaign encourages people to start conversations with their mothers and loved ones about heart disease, including high blood pressure and heart valve failure, to better understand their family health history and risk factors. The campaign is part of the company's ongoing commitment to leading and advancing clinical research for women's health and was supported by the Medtronic Coronary & Renal Denervation and Structural Heart & Aortic businesses. To learn more about heart disease including signs, symptoms, treatment options and resources to start the conversation today, visit ALettertomyMother.com.

    About Medtronic

    Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

    Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

    Contacts:

    Kimberly Powell

    Public Relations

    +1-202-498-2601

    Ryan Weispfenning

    Investor Relations

    +1-763-505-4626

    1 Caoimhe T Rice, Sophie Barnett, Shea P O'Connell, Enoch Akowuah, Clare E Appleby, John B Chambers, Benoy N Shah, Daniel J Blackman - Impact of gender, ethnicity and social deprivation on access to surgical or transcatheter aortic valve replacement in aortic stenosis: a retrospective database study in England: Open Heart 2023;10:e002373.

     

    (PRNewsfoto/Medtronic plc)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/new-survey-1-in-3-women-have-not-talked-to-their-doctor-about-heart-health-the-1-killer-of-women-302448627.html

    SOURCE Medtronic plc

    Get the next $MDT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    2/13/2026$116.00Overweight
    Barclays
    2/9/2026$121.00Hold → Buy
    Needham
    2/3/2026$117.00Buy
    Citigroup
    1/30/2026$114.00Overweight
    Wells Fargo
    1/6/2026Mkt Perform → Outperform
    William Blair
    11/19/2025$111.00Sell → Neutral
    Goldman
    6/30/2025Underperform → Peer Perform
    Wolfe Research
    6/16/2025$110.00Outperform
    Leerink Partners
    More analyst ratings

    $MDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Medtronic Plc claimed ownership of 252,813,348 shares (SEC Form 3)

    3 - Medtronic plc (0001613103) (Reporting)

    3/5/26 8:39:25 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & Chief Financial Officer Pieton Thierry covered exercise/tax liability with 2,976 units of Ordinary Shares, decreasing direct ownership by 7% to 37,574 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    3/5/26 5:22:16 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EVP & President Cardiovascular Kiil Harry Skip exercised 50,876 units of Ordinary Shares at a strike of $90.90 and sold $5,132,217 worth of Ordinary Shares (52,524 units at $97.71), decreasing direct ownership by 5% to 32,768 units (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    2/26/26 5:48:47 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Medtronic plc.

    SCHEDULE 13G/A - Medtronic plc (0001613103) (Subject)

    3/27/26 10:30:11 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic plc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Medtronic plc (0001613103) (Filer)

    3/24/26 4:42:04 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Medtronic plc.

    10-Q - Medtronic plc (0001613103) (Filer)

    2/24/26 4:18:20 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Medtronic to announce financial results for its fourth quarter and full fiscal year 2026

    GALWAY, Ireland, April 13, 2026 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results on Wednesday, June 3, 2026, for its fourth quarter and full fiscal year 2026, which ends on Friday, April 24, 2026.A news release containing summary financial information will be issued at 5:45 a.m. Central Time (CT) and will be available at https://news.medtronic.comA video webcast to discuss results will begin at 6:45 a.m. CT and can be accessed at https://investorrelations.medtronic.comWithin 24 hours of the video webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at

    4/13/26 6:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Telix Strengthens Board with Additional Director Appointments

    MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata

    4/8/26 6:44:20 PM ET
    $ANIK
    $AVNT
    $COO
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

    Medtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures

    GALWAY, Ireland, March 27, 2026 /PRNewswire/ -- Medtronic (NYSE:MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance of the Stealth AXiS™ surgical system for cranial and ear, nose, and throat (ENT) procedures. Cleared for spine procedures in February, the Stealth AXiS™ surgical system unifies surgical planning, navigation, and robotics into a single intelligent system to support surgeons with greater precision and real-time insights during complex procedures. This clearance reinforces Medtronic's strategy to deliver connected technologies that support surgeons across multiple specialties on a single platform."Cranial procedures req

    3/27/26 9:00:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Jellison William R bought $462,750 worth of Ordinary Shares (5,000 units at $92.55) (SEC Form 4)

    4 - Medtronic plc (0001613103) (Issuer)

    8/25/25 5:18:06 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Barclays resumed coverage on Medtronic with a new price target

    Barclays resumed coverage of Medtronic with a rating of Overweight and set a new price target of $116.00

    2/13/26 8:31:53 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic upgraded by Needham with a new price target

    Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00

    2/9/26 6:45:10 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Citigroup resumed coverage on Medtronic with a new price target

    Citigroup resumed coverage of Medtronic with a rating of Buy and set a new price target of $117.00

    2/3/26 6:56:06 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Leadership Updates

    Live Leadership Updates

    View All

    Medtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company

    GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to become fully independent.  Chad brings over 25 years of financial leadership experience across healthcare, consumer, and industrial sectors. Most recently, he served as CFO at BIC (BB:PA), a pu

    7/8/25 8:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic Board appoints Dr. Joon Lee as a new director

    GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board. "We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtronic's Board of Directors," said Geoff Martha, chairman and chief executive officer. "Dr. Lee brings deep expertise as a clinical researcher, academic leader, and physician executive with dec

    6/23/25 4:15:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

    NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO, "Orchestra BioMed" or the "Company")), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update. "We remain highly focused on execution of the BACKBEAT global pivotal study, which we believe has the potential to deliver landmark results that can establish AVIM therapy as a new standard of care for the treatment of uncontrolled hypertension in patients already indicated for a pacemaker. We also believe it can lay the foundation for

    3/31/25 4:21:30 PM ET
    $MDT
    $OBIO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medicinal Chemicals and Botanical Products

    $MDT
    Financials

    Live finance-specific insights

    View All

    Medtronic announces cash dividend for fourth quarter of fiscal year 2026

    GALWAY, Ireland, March 5, 2026 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 5, 2026, approved the company's cash dividend for the fourth quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on April 17, 2026, to shareholders of record at the close of business on March 27, 2026.About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquarte

    3/5/26 4:53:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters

    Cardiovascular portfolio up 11% year-over-year; Cardiac Ablation Solutions grew 80% on strength of pulsed field ablation portfolioGALWAY, Ireland, Feb. 17, 2026 /CNW/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 (FY26), which ended January 23, 2026.Q3 Key HighlightsRevenue of $9.0 billion, increased 8.7% as reported and 6.0% organic, 50 basis points ahead of Q3 guidanceGAAP diluted EPS of $0.89; non-GAAP diluted EPS of $1.36, three cents ahead of Q3 guidance mid-pointCompany reiterates FY26 organic revenue growth and EPS guidanceCardiac Ablation Solutions revenue increased 80%, includin

    2/17/26 6:45:00 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Medtronic announces cash dividend for third quarter of fiscal year 2026

    GALWAY, Ireland, Dec. 4, 2025 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 4, 2025, approved the company's cash dividend for the third quarter of fiscal year 2026 of $0.71 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2025. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 48 consecutive years. The dividend is payable on January 16, 2026, to shareholders of record at the close of business on December 26, 2025. About MedtronicBold thinking. Bolder actions. We are Medtronic. Medtronic plc, hea

    12/4/25 4:32:00 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $MDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/13/24 5:09:43 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/12/24 1:59:55 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by Medtronic plc. (Amendment)

    SC 13G/A - Medtronic plc (0001613103) (Subject)

    2/15/23 3:34:14 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care